Heterozygous Mutations in AAGAB Cause Type 1 Punctate Palmoplantar Keratoderma with Evidence for Increased Growth Factor Signaling

ex vivo virus infection of LCs as well as subsequent virus transmission when different R5 HIV strains, HIVAD8 and HIVJR-FL, were utilized for an additional six subjects (n1⁄43 for each strain, Figures 1 and 2). These data demonstrate that oral administration of MVC for at least 3 days is capable of fully protecting HIV infection of LCs within epithelial tissue. These experiments provide perhaps the best proof-of-concept test for MVC as a potential PrEP drug, as it would be unethical to expose MVC-treated volunteers to HIV in vivo. As proven here, orally delivered MVC rapidly distributes to skin and functionally acts to block infection of relevant target cells, LCs, supporting randomized controlled trials of MVC as a PrEP therapy for individuals at high risk of becoming infected with HIV through sexual exposure.